88% objective response rate bispecific antibody preliminary clinical results released
Studies have found that the persistent presence of antibodies in COVID-19 patients can reduce the risk of reinfection for up to six months
2021 ESMO: Corning Jerry announces the latest clinical data of two dual antibodies, PD-L1/CTLA-4
Blockbuster: The first clinical results of the first domestic CD3 recruiting bi-antibody phase I are released
Cinda’s first SIRPα antibody, will CD47/SIRPα be the next piece of the Red Sea?
Hebo Pharma's new-generation anti-CTLA-4 antibody HBM4003 was approved for two clinical trials in China
42 new drugs have been approved for clinical use, and dual-antibody drugs have exploded!
CStone's multispecific antibody CS2006/NM21-1480 China clinical trial application approved
Medrxiv: Antibody levels have soared 78 times!
The CD20xCD3 bispecific antibody CM355 jointly developed by Nuocheng Jianhua and Connoa was approved for clinical use
Development of mRNA-encoded antibody therapy Moderna and AbCellera reach a partnership
BeiGene PD1 monoclonal antibody combined with DKK1 monoclonal antibody for first-line treatment of gastric cancer ORR reached 68.2%
Hebo Pharmaceutical Announces Positive Results of Phase I Study of New Generation Anti-CTLA-4 Antibody HBM4003
The GD2 antibody new drug market application introduced by Saisheng Pharmaceutical is planned to be included in the priority review
Junshi/Lilly's new crown neutralizing antibody cocktail therapy resumes distribution in the United States
Innovent and Bolt reached an agreement to jointly develop three anti-tumor drugs using antibody-immune stimulation coupling technology
Janssen's potential "first-in-class" bispecific antibody is clinically approved in China
: The opportunities for listed drugs before 2016 are elusive, and monoclonal antibodies and tinib are still active
neutralizing antibody combination against new coronavirus mutant strains
Fast and sensitive on-site detection technology for new coronavirus antibodies